ArticleParasites & vectors2025
Comparative immunoinformatic analysis of Rhipicephalus microplus cocktail vaccine targets.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe cattle fever tick, Rhipicephalus microplus, is found in tropical and subtropical regions worldwide. Infestations of this tick lead to significant economic losses for cattle producers and dairy farmers, and the ticks can transmit a variety of pathogens that cause diseases such as babesiosis, anaplasmosis and theileriosis. The proteins Bm86, AQP1, AQP2 and VgR are expressed in various tick tissues, including the gut, salivary glands and ovaries. These proteins regulate essential physiological processes, including water balance (AQP1, AQP2), reproduction (VgR) and cell membrane integrity (Bm86).
methodsComprehensive bioinformatic and immunoinformatic analyses were conducted to evaluate Bm86, AQP1, AQP2 and VgR as potential vaccine targets against R. microplus. Specifically, we conducted studies on these proteins that included analysis of their physicochemical properties; topographical protein analyses; prediction of N-glycosylation sites, O-glycosylation sites, phosphorylation sites and B-cell and T-cell epitopes; and immune response simulation. The overall aim was to identify key epitopes and highlight their behavior within the host, representing a promising multicomponent vaccine formulation.
resultsThe predictions for R. microplus Bm86, VgR, AQP1 and AQP2 proteins indicate strong antigenicity, low allergenicity and minimal toxicity, suggesting the potential for safe and effective immune response elicitation. The immune profile simulations for a cocktail of these proteins as vaccine candidates predicted consistently high levels of interferon-gamma and antibody isotypes, which could improve vaccine efficacy and control tick fitness and survivability in subsequent generations.
conclusionsThe application of immunoinformatic tools for anti-tick vaccination was validated for the investigation of combining R. microplus Bm86, VgR, AQP1 and AQP2 proteins as a potential cocktail vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.